Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPT: Phage Therapy and Antibiotics in Cystic Fibrosis
NCT07280598Phase 1Not yet recruiting
- Sponsor
- University of California, San Diego
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Microbiome Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of bacteriophage cocktail in cystic fibrosis (CF) and bacterial infection, sponsored by University of California, San Diego. Primary endpoint: Safety and tolerability of combined IV antibiotic and bacteriophage therapy at Day 28. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
bacteriophage cocktail
03
Conditions
cystic fibrosis (CF)bacterial infection
Beyond the preview
Go deeper on NCT07280598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07280598.